



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RU-0242

Inventors: Yurkow and Mermelstein

Serial No.: 10/522,092

Filing Date: Not Yet Assigned

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Title: Method for Treating Cancer

I, Jane Massey Licata, Registration No. 32,257, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450

On this date: March 8, 2005

Jane Massey Licata
Jane Massey Licata, Registration No. 32,257

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into

the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

() Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

() Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 10/228,644, filed August 26, 2002, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.


Respectfully submitted,

Jane Massey Licata
Registration No. 32,257


Date: March 8, 2005

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Form PTO-1449 Modified		Docket No. RU-0242	Serial No. 10/522,092
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Yurkow and Mermelstein	
		Filing Date Not Yet Assigned	Group Not Yet Assigned
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Bernard et al., "Modulation of glutathione level during butyrate-induced differentiation in human colon derived HT-29 cells", <i>Molecular and Cellular Biochem.</i> 1997 170:109-114	
	AB	Gleave et al., "Butyrate Analogue, Isobutyramide, Inhibits Tumor Growth and Time to Androgen-Independent Progression in the Human Prostate LNCaP Tumor Model" <i>J. Cell. Biochem.</i> 1998 69:271-281	
	AC	Neal et al., "Effects of N-acetylcysteine and 2,3-dimercaptosuccinic acid on lead induced oxidative stress in rat lenses", <i>Toxicology</i> 1998 130:167-174	
	AD	Blomgren et al., "Antitumor Activity of 2-Mercaptoethanesulfonate (Mesna) In Vitro", <i>Meth Find Exp Clin Pharmacol</i> 1990 12(10):691-697	
	AE	Russo P., "Urologic Emergencies in the Cancer Patient", <i>Seminars in Oncology</i> 2000 27(3):284-298	
EXAMINER		DATE CONSIDERED	



Sheet 02 of 02

Form PTO-1449 Modified

Docket No.
RU-0242Serial No.
10/522,092List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)Applicant
Yurkow and Mermelstein

U.S. Department of Commerce

Filing Date
Not Yet AssignedGroup
Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	BA	5,019,596	5-28-91	Reiner et al.	514	578
	BB	6,025,488	2-15-00	Hausheer	540	454
	BC	6,066,645	5-23-00	Hausheer et al.	514	283

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	

EXAMINER

DATE CONSIDERED